Switch theme
Sign up to access all valuation multiples
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
2007
395
LTM Revenue $347M
LTM EBITDA -$16.9M
$818M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ardelyx has a last 12-month revenue (LTM) of $347M and a last 12-month EBITDA of -$16.9M.
In the most recent fiscal year, Ardelyx achieved revenue of $334M and an EBITDA of -$16.7M.
Ardelyx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ardelyx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $347M | XXX | $334M | XXX | XXX | XXX |
| Gross Profit | $300M | XXX | $283M | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | -$16.9M | XXX | -$16.7M | XXX | XXX | XXX |
| EBITDA Margin | -5% | XXX | -5% | XXX | XXX | XXX |
| EBIT | -$47.9M | XXX | -$27.9M | XXX | XXX | XXX |
| EBIT Margin | -14% | XXX | -8% | XXX | XXX | XXX |
| Net Profit | -$61.7M | XXX | -$39.1M | XXX | XXX | XXX |
| Net Margin | -18% | XXX | -12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $85.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ardelyx's stock price is $4.
Ardelyx has current market cap of $877M, and EV of $818M.
See Ardelyx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $818M | $877M | XXX | XXX | XXX | XXX | $-0.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ardelyx has market cap of $877M and EV of $818M.
Ardelyx's trades at 2.5x EV/Revenue multiple, and -48.9x EV/EBITDA.
Equity research analysts estimate Ardelyx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ardelyx has a P/E ratio of -14.2x.
See valuation multiples for Ardelyx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $877M | XXX | $877M | XXX | XXX | XXX |
| EV (current) | $818M | XXX | $818M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | -48.5x | XXX | -48.9x | XXX | XXX | XXX |
| EV/EBIT | -17.1x | XXX | -29.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -14.2x | XXX | -22.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -17.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArdelyx's last 12 month revenue growth is 21%
Ardelyx's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.8M for the same period.
Ardelyx's rule of 40 is -24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ardelyx's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ardelyx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | -5% | XXX | -5% | XXX | XXX | XXX |
| EBITDA Growth | -226% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -24% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 93% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ardelyx acquired XXX companies to date.
Last acquisition by Ardelyx was XXXXXXXX, XXXXX XXXXX XXXXXX . Ardelyx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ardelyx founded? | Ardelyx was founded in 2007. |
| Where is Ardelyx headquartered? | Ardelyx is headquartered in United States of America. |
| How many employees does Ardelyx have? | As of today, Ardelyx has 395 employees. |
| Who is the CEO of Ardelyx? | Ardelyx's CEO is Mr. Michael G. Raab. |
| Is Ardelyx publicy listed? | Yes, Ardelyx is a public company listed on NAS. |
| What is the stock symbol of Ardelyx? | Ardelyx trades under ARDX ticker. |
| When did Ardelyx go public? | Ardelyx went public in 2014. |
| Who are competitors of Ardelyx? | Similar companies to Ardelyx include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ardelyx? | Ardelyx's current market cap is $877M |
| What is the current revenue of Ardelyx? | Ardelyx's last 12 months revenue is $347M. |
| What is the current revenue growth of Ardelyx? | Ardelyx revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Ardelyx? | Current revenue multiple of Ardelyx is 2.4x. |
| Is Ardelyx profitable? | Yes, Ardelyx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ardelyx? | Ardelyx's last 12 months EBITDA is -$16.9M. |
| What is Ardelyx's EBITDA margin? | Ardelyx's last 12 months EBITDA margin is -5%. |
| What is the current EV/EBITDA multiple of Ardelyx? | Current EBITDA multiple of Ardelyx is -48.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
